6-K 1 d764136d6k.htm FORM 6-K FORM 6-K





Washington, D.C. 20549



Form 6-K




PURSUANT TO RULE 13a-16 OR 15d-16


For the month of August, 2019

Commission File Number                         



Kazia Therapeutics Limited

(Translation of registrant’s name into English)



Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☑             Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  ☐     No  ☑

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

Kate Hill

Kate Hill

Company Secretary

Date 13 August 2019



13 August 2019


Sydney, 13 August 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has completed recruitment of patients into Part B of its phase I clinical study of Cantrixil in ovarian cancer.

Dr James Garner, Chief Executive Officer of Kazia Therapeutics commented, “Part B of the Cantrixil study has recruited well and we are now following patients through to completion of their treatment. We are grateful for the excellent efforts of the participating clinicians, and of the study team. The first part of the study has shown some very promising signals, and the data from Part B will significantly enhance our understanding of the drug. We will be presenting data at the ESMO conference at the end of September, and this will be valuable opportunity to move forward our partnering discussions for Cantrixil.”

Key Points



Part A of the study collected data from an initial 14 patients, who received escalating doses of Cantrixil to determine safety and tolerability. A maximum tolerated dose of 5 mg/kg was achieved, and this data was reported at the American Association of Cancer Research conference on 1 April 2019.



Part B was designed to enroll 12 patients, all of whom receive Cantrixil at a dose of 5 mg/kg. Part B was designed to seek preliminary signals of potential efficacy for the drug.



Initial data from Part B is expected in the fourth quarter of calendar 2019, with final completion of the study in 2020.

Kazia was pleased to present positive data from the first part (Part A) of the study at the American Association of Cancer Research (AACR) on 1 April 2019. The data showed that, of nine patients evaluable for efficacy, five (56%) achieved a best observed response of stable disease after two cycles of Cantrixil monotherapy. One of these five patients subsequently achieved a partial response when Cantrixil was administered with chemotherapy. The study also determined a Maximum Tolerated Dose (MTD) of 5 mg/kg, which is the dose that is being used for all patients in Part B of the study.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

Final data from these nine patients in Part A, including from the off-treatment follow-up period, has been selected for presentation at the European Society of Medical Oncology Annual Meeting in Barcelona, Spain on 27 September – 1 October 2020.

The phase I study of Cantrixil commenced in December 2016 and is registered on clinicaltrials.gov as NCT02903771. The study is being conducted at six hospitals in the United States and Australia:-




Principal Investigator

United States


Lifespan Cancer Institute, Providence, RI

   Dr. Don Dizon

Stephenson Cancer Center, Oklahoma City , OK

   Assoc. Prof. Kathleen Moore

Mary Crowley Cancer Research Centre, Dallas, TX

   Dr. Minal Barve



ICON Cancer Care, Brisbane, QLD

   Assoc. Prof. Jermaine Coward

Westmead Hospital, Sydney, NSW

   Prof. Paul Harnett

Flinders Medical Centre, Adelaide, SA

   Dr. Ganessan Kichenadasse

Approximately 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women. Conventional treatment typically includes surgery, radiotherapy, and chemotherapy. However, the five-year survival rate remains low, at approximately 45%, reflecting the fact that the disease is often advanced at the time of diagnosis.


About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019, and efficacy data is expected in 2H 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented at the AACR annual conference in April 2019 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.